Evaluation of Burkholderia cepacia Complex Bacteria Pathogenicity Using Caenorhabditis elegans

Tedesco, Pietro; Di Schiavi, Elia; Esposito, Fortunato Palma; de Pascale, Donatella

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Evaluation of Burkholderia cepacia Complex Bacteria Pathogenicity Using Caenorhabditis elegans

Published Date:

Oct 20 2016

Source:

Bio Protoc. 6(20).

[PDF - 102.28 KB]

Details:

Personal Authors:

Tedesco, Pietro ; Di Schiavi, Elia ; Esposito, Fortunato Palma ; de Pascale, Donatella ;

Pubmed ID:

28255573

Pubmed Central ID:

PMC5330310

Description:

This protocol describes two biological assays to evaluate pathogenicity of Burkholderia cepacia complex (Bcc) strains against the nematode Caenorhabditis elegans. Specifically, these two assays allow one to identify if the under-investigated Bcc strains are able to kill the nematodes by intestinal colonization (slow killing assay, SKA) or by toxins production (fast killing assay, FKA). The principal differences between the two assays rely on the different killing kinetics for worms.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

P40 OD010440/OD/NIH HHS/United States
U66 IP000114/IP/NCIRD CDC HHS/United States

Supporting Files:

nihms844603.nxml	application/octet-stream
nihms844603f1.gif	image/gif
nihms844603f1.jpg	image/jpeg

No Related Documents.

You May Also Like:

Manufacturer’s recall of nasal spray contaminated with Burkholderia cepacia complex

Corporate Author:

Centers for Disease Control and Prevention (U.S.)

Published:

3/24/04

Source:

HAN ; 191

Series:

HAN ; 191

Description:

Wednesday, March 24, 2004, 16:12 EST (04:12 PM EST) : CDCHAN-00191-2004-03-24-ADV-N : Clinicians should be aware that the Centers for Disease Control and Prevention (CDC) has been notified of a voluntary recall of over-the-counter oxymetazoline HCL 0...

File Type:

[PDF - 716.64 KB]
Manufacturer’s recall of nasal spray contaminated with Burkholderia cepacia complex

Corporate Author:

Centers for Disease Control and Prevention (U.S.)

Published:

3/25/04

Source:

HAN ; 192

Series:

HAN ; 192

Description:

March 25, 2004, 11:20 EST (11:20 AM EST) : CDCHAN-00192-04-03-25-UPD-N : Clinicians should be aware that the Centers for Disease Control and Prevention (CDC) has been notified of a voluntary recall of over-the-counter oxymetazoline HCL 0.05% nasal sp...

File Type:

[PDF - 787.49 KB]
Manufacturer’s recall of nasal spray contaminated with Burkholderia cepacia complex

Corporate Author:

Centers for Disease Control and Prevention (U.S.)

Published:

3/26/04

Source:

HAN ; 193

Series:

HAN ; 193

Description:

Friday, March 26, 2004, 17:55 EDT (5:55 PM EDT) : CDCHAN-00193-2004-03-26-UPD-N : Clinicians should be aware that the Centers for Disease Control and Prevention (CDC) has been notified that additional lots of over-the-counter oxymetazoline HCL 0.05% ...

File Type:

[PDF - 775.36 KB]
Epidemiology of Burkholderia cepacia Complex in Patients with Cystic Fibrosis, Canada

Personal Author:

Speert, David P.; Henry, Deborah; Vandamme, Peter; Corey, Mary; Mahenthiralingam, Eshwar;

Published:

Feb 2002

Source:

Emerg Infect Dis. 8(2):181-187.

Description:

The Burkholderia cepacia complex is an important group of pathogens in patients with cystic fibrosis (CF). Although evidence for patient-to-patient spread is clear, microbial factors facilitating transmission are poorly understood. To identify microb...

File Type:

[PDF - 74.51 KB]
Commercial use of Burkholderia cepacia.

Personal Author:

LiPuma, J. J.; Mahenthiralingam, E.;

Published:

1999 Mar-Apr

Source:

Emerg Infect Dis. 5(2):305-306.

File Type:

[PDF - 61.04 KB]